Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27774606 | 0.91 | LMNA (0.38) | DNM1TSHRFDPS | |
| SCHEMBL3391758 | 0.90 | ADRB2 (0.36) | DNM1CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL6702494 | 0.89 | TSHR (0.43) | DNM1ALDH1A1TSHRCA1CA2 | |
| SCHEMBL2803830 | 0.84 | — | — | |
| SCHEMBL27882987 | 0.83 | DNM1 (0.39) | DNM1ALDH1A1TSHRADRB2ADRB1 | |
| SCHEMBL3389854 | 0.82 | CYP3A4 (0.32) | DNM1CYP3A4ALDH1A1TSHR | |
| SCHEMBL11823405 | 0.82 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL386798 | 0.82 | — | — | |
| SCHEMBL21224549 | 0.81 | DNM1 (0.42) | DNM1TSHRFDPS | |
| SCHEMBL21225211 | 0.81 | DNM1 (0.42) | DNM1TSHRFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404860-B2 | Compound having hydantoin ring and method of producing the same | TOKUYAMA CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20120289705-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | SHIIGI HIROFUMI (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8258313-B2 | Compound having hydantoin ring and method of producing the same | TOKUYAMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20100184993-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | TOKUYAMA CORPORATION (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2172459-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | Tokuyama Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-1556346-A1 | 1-PHENYLPYRROLIDINE-2-ONE-3-CARBOXAMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037787-A1 | 1-PHENYLPYRROLIDINE-2-ONE-3-CARBOXAMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-06 | — | — | WO | disclosed |
| CN-1105799-A | Carbostyril derivatives as matrix metalloproteinases inhibitors | OTSUKA PHARMA CO LTD (JP) | 1995-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289705-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | CASP14, CYP8B1, DDT | DNM1 1318/4885CYP3A4 92/4885ALDH1A1 2059/4885 |
| US-20100184993-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | CASP14, CYP8B1, DDT | DNM1 1318/4885CYP3A4 92/4885ALDH1A1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.